Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „subjects“
Suchtreffer
Begriffe & Kennungen
Abseamed · 4.8 · Of a total 3 417 subjects in 25 randomised, double-blinded, placebo or standard of care controlled studies, th
Eintrag öffnenAccofil · 4.8 · 33 There is insufficient data to further evaluate filgrastim use in paediatric subjects.
Eintrag öffnenAccofil · 4.8 · Geriatric Use No overall differences in safety or effectiveness were observed between subjects over 65 years o
Eintrag öffnenAccofil · 4.8 · Geriatric Use No overall differences in safety or effectiveness were observed between subjects over 65 years o
Eintrag öffnenAccofil · 4.8 · Geriatric use No overall differences in safety or effectiveness were observed between subjects over 65 years o
Eintrag öffnenAccofil · 4.8 · Geriatric use No overall differences in safety or effectiveness were observed between subjects over 65 years o
Eintrag öffnenAccofil · 4.8 · There is insufficient data to further evaluate filgrastim use in paediatric subjects.
Eintrag öffnenAccofil · 4.8 · There is insufficient data to further evaluate filgrastim use in paediatric subjects.
Eintrag öffnenAccofil · 4.8 · There is insufficient data to further evaluate filgrastim use in paediatric subjects.
Eintrag öffnenAdenuric · 4.5 · Theophylline An interaction study in healthy subjects has been performed with febuxostat to evaluate whether t
Eintrag öffnenAdenuric · 4.5 · Theophylline An interaction study in healthy subjects has been performed with febuxostat to evaluate whether t
Eintrag öffnenAdenuric · 4.8 · Summary of the safety profile The most commonly reported adverse reactions in clinical trials (4,072 subjects
Eintrag öffnenAdenuric · 4.8 · Summary of the safety profile The most commonly reported adverse reactions in clinical trials (4,072 subjects
Eintrag öffnenAdtralza · 4.8 · Eczema herpeticum Eczema herpeticum was reported in 0.3% of the subjects treated with tralokinumab and in 1.5%
Eintrag öffnenAdtralza · 4.8 · Keratitis was reported in 0.5% of subjects treated with tralokinumab during the initial treatment period. Of t
Eintrag öffnenAdvate · 4.8 · Clinical studies with ADVATE included 418 subjects with at least one exposure to ADVATE reporting in total 93
Eintrag öffnenAdvate · 4.8 · Clinical studies with ADVATE included 418 subjects with at least one exposure to ADVATE reporting in total 93
Eintrag öffnenAdynovi · 4.8 · None of the subjects who participated in one or more of 6 completed clinical trials in PTPs developed persiste
Eintrag öffnenAdynovi · 4.8 · None of the subjects who participated in one or more of 6 completed clinical trials in PTPs developed persiste
Eintrag öffnenAkantior · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Subjects with urge
Eintrag öffnen